REVANCE THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.4 USD | +3.34% |
|
-10.05% | -61.32% |
| Apr. 26 | AbbVie raises annual profit forecast on strong Skyrizi sales | RE |
| Apr. 12 | Revance Therapeutics, Inc. to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting | CI |
Quotes 5-day view
Delayed Quote Nasdaq| 2024-04-23 | 2024-04-24 | 2024-04-25 | 2024-04-26 | |
|---|---|---|---|---|
| Last | 3.66 $ | 3.57 $ | 3.29 $ | 3.4 $ |
| Volume | 1 588 720 | 1 789 023 | 2 646 582 | 2 280 332 |
| Change | +0.55% | -2.46% | -7.84% | +3.34% |
| Opening | 3.64 | 3.64 | 3.50 | 3.36 |
| High | 3.81 | 3.75 | 3.50 | 3.56 |
| Low | 3.62 | 3.54 | 3.23 | 3.21 |
Performance
| 1 day | +3.34% | ||
| 1 week | -10.05% | ||
| Current month | -30.89% | ||
| 1 month | -27.66% | ||
| 3 months | -42.95% | ||
| 6 months | -57.18% | ||
| Current year | -61.32% | ||
| 1 year | -89.21% | ||
| 3 years | -88.46% | ||
| 5 years | -74.65% | ||
| 10 years | -90.10% |
Volumes
marketsDaily volume
2 280 332
Estimated daily volume
2 280 332
Avg. Volume 20 sessions
1 752 483
Daily volume ratio
1.30
Avg. Volume 20 sessions USD
5 958 442.20
Record volume 1
17 254 810
Record volume 2
13 135 267
Record volume 3
11 658 040
Capital turnover ratio
0.02
Float rotation
0.02
Basic data
Capitalization (USD)
354 333 087
Net sales (USD)
234 040 000
Number of employees
597
Sales / Employee (USD)
392 027
Free-Float
91.53 %
Free-Float capitalization (USD)
324 311 203
Average Daily Capital Traded
1.68%
Highs and lows
1 week
3.21
3.87
1 month
3.215.03
Current year
3.219.75
1 year
3.2137.98
3 years
3.2137.98
5 years
3.2137.98
10 years
3.2142.41
Indicators
Moving average 5 days
3.51
Moving average 20 days
4.15
Moving average 50 days
5.04
Moving average 100 days
5.94
Price spread / (MMA5)
+3.29%
Price spread / (MMA20)
+21.94%
Price spread / (MMA50)
+48.34%
Price spread / (MMA100)
+74.78%
STIM
RSI 9 days
16.04
RSI 14 days
23.65
Sector Comparison - Biopharmaceuticals
| Name | Change | 5d. change | 1st Jan change | 1-year change | Capi. | |
|---|---|---|---|---|---|---|
| +3.34% | -10.05% | -61.32% | -89.21% | 354M | ||
| -1.85% | +1.41% | -4.66% | -10.60% | 86.13B | ||
| -1.28% | -1.41% | +1.32% | -1.66% | 39.82B | ||
| +3.18% | +7.47% | -19.27% | -27.48% | 30.42B | ||
| +0.65% | +2.76% | +57.86% | +46.08% | 25.23B | ||
| -1.53% | -8.71% | -16.09% | -13.00% | 15.35B | ||
| +7.67% | +2.31% | -9.14% | -9.50% | 11.95B | ||
| +0.98% | -1.28% | -17.69% | -29.72% | 11.6B | ||
| +1.81% | -13.98% | -43.00% | -35.34% | 11.51B | ||
| +0.07% | +7.66% | +5.24% | +7.25% | 8.71B | ||
| +1.56% | +17.92% | -8.42% | +2.49% | 8.12B | ||
| +1.57% | +1.23% | +2.29% | +20.02% | 7.72B | ||
| 0.00% | +3.15% | +76.35% | +283.44% | 6.69B | ||
| -0.96% | +2.57% | -10.12% | +16.72% | 6.59B | ||
| -0.80% | -0.49% | -7.72% | +6.85% | 6.49B | ||
| +4.03% | +4.90% | -16.71% | -41.12% | 6.01B | ||
| Average | +1.15% | +0.84% | -4.44% | +7.83% | ||
| Weighted average by Cap. | +0.15% | +0.95% | -0.94% | +1.03% |
Historical data
| Date | Opening | High | Low | End-of-day | Volume |
|---|
Last transactions
f89f1b3fca5586ca73a1bd22343c.u52LSg47_jt08hr_zpDjMv_DIPTeF0FDJZPnqzRr2hY._-jBCWlZql4tm1ixv9fQQqeXb7uVeHIXa-q-80cjsWP21PglPUiScQffXw
| Date | Price | Volume | Daily volume |
|---|---|---|---|
| 04:00:00 pm | 3.4 | 248,703 | 2,061,481 |
| 04:00:00 pm | 3.4 | 500 | 1,812,778 |
| 04:00:00 pm | 3.4 | 4,916 | 1,812,278 |
| 04:00:00 pm | 3.4 | 300 | 1,807,362 |
| 04:00:00 pm | 3.4 | 137 | 1,807,062 |
| 04:00:00 pm | 3.4 | 5,300 | 1,806,925 |
| 04:00:00 pm | 3.4 | 4,400 | 1,801,625 |
| 04:00:00 pm | 3.4 | 100 | 1,797,225 |
| 04:00:00 pm | 3.4 | 1,100 | 1,797,125 |
| 04:00:00 pm | 3.4 | 423 | 1,796,025 |
Monthly variations
Annual change
| 2024 | -61.32% | ||
| 2023 | -52.38% | ||
| 2022 | +13.11% | ||
| 2021 | -42.41% | ||
| 2020 | +74.61% | ||
| 2019 | -19.37% | ||
| 2018 | -43.69% | ||
| 2017 | +72.71% | ||
| 2016 | -39.40% | ||
| 2015 | +101.65% | ||
| 2014 | -36.91% |
- Stock Market
- Equities
- RVNC Stock
- Quotes Revance Therapeutics, Inc.
